Log in
Enquire now
‌

US Patent 11834455 Carm1 inhibitors and uses thereof

Patent 11834455 was granted and assigned to Epizyme on December, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Epizyme
Epizyme
0
Current Assignee
Epizyme
Epizyme
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
118344550
Patent Inventor Names
Gideon Shapiro0
Oscar Miguel Moradei0
Lei Jin0
Robert E. Babine0
Richard Chesworth0
Date of Patent
December 5, 2023
0
Patent Application Number
168224780
Date Filed
March 18, 2020
0
Patent Citations
‌
US Patent 8338437 Amines as small molecule inhibitors
0
‌
US Patent 8906900 PRMT5 inhibitors and uses thereof
0
‌
US Patent 8940726 PRMT5 inhibitors and uses thereof
0
‌
US Patent 8952026 PRMT1 inhibitors and uses thereof
0
‌
US Patent 8993555 PRMT5 inhibitors and uses thereof
0
‌
US Patent 9023883 PRMT1 inhibitors and uses thereof
0
‌
US Patent 9045455 Arginine methyltransferase inhibitors and uses thereof
0
‌
US Patent 9120757 Arginine methyltransferase inhibitors and uses thereof
0
...
Patent Primary Examiner
‌
Michael Barker
0
No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11834455 Carm1 inhibitors and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.